

1 *Review*

2 **Effects of COVID-19 infection during pregnancy and** 3 **neonatal prognosis: what is the evidence?**

4 Álvaro Francisco Lopes Sousa^{1,2*}, Herica Emilia Félix de Carvalho², Layze Braz de Oliveira²,
5 Guilherme Schneider², Emerson Lucas Silva Camargo², Evandro Watanabe², Denise de Andrade²;
6 Ana Fátima Carvalho Fernandes³, Isabel Amélia Costa Mendes², Inês Fronteira¹

7 ¹Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de
8 Lisboa, Lisboa, Portugal.

9 ²Network in Exposome Human and Infectious Diseases, Universidade de São Paulo, São Paulo, Brazil.

10 ³Infectious Diseases Department, Universidade Federal do Ceará, Fortaleza, Brazil.

11 *Correspondence:

12 sousa.alvaromd@gmail.com; alvarosousa@usp.br

13 Received: date; Accepted: date; Published: date

14 **Background:** Little is known about how COVID-19 infection affects pregnant women, as well as
15 about the possibility of vertical transmission or complications in childbirth. This study's aims to
16 assess the current evidence presented in the literature regarding the potential risks of COVID-19
17 infection among pregnant women and consequent fetal transmission. **Methods:** a systematic
18 literature review assessing papers published in the most comprehensive databases in the field of
19 health, intended to answer the question: "What are the effects of COVID-19 infection during
20 pregnancy and what is the neonatal prognosis?" **Results:** 42 papers published in 2020 were eligible.
21 Were included 19 case reports (45%), 15 cross-sectional descriptive studies (35%), 6 cross-sectional
22 analytical studies (14%), one case-control study (3%) and one cohort study (3%), presenting low
23 levels of evidence. A total of 650 pregnant women and 511 infants were assessed. More than half of
24 pregnant women having cesarean deliveries (324/64%). Only 410 (80%) infants were tested for
25 SARS-CoV-2, of which 8 (2%) were positive, however, based on what was assessed that there is no
26 evidence of vertical transmission so far, as there are gaps concerning the care taken during and
27 after delivery, and biological sample proper for testing the SARS-CoV-2. **Conclusions:** health
28 professionals cannot rule out a possible worsening of the clinical picture of the pregnant woman
29 infected with SARS-CoV-2 because she is asymptomatic or does not have comorbidities related to
30 gestation. Pregnant women and health professionals should be cautious and vigilant, as soon as
31 their pregnancy is confirmed, with or without confirmed infection, as this review checks for
32 infected pregnant women in all trimesters of pregnancy.

33 **Keywords:** COVID-19; SARS-CoV-2; Pregnancy; Fetal transmission; mother-to-child transmission.

34 **1. Introduction**

35 The World Health Organization (OMS) declared on January 30th, 2020, that the outbreak of
36 COVID-19, a respiratory disease caused by the new coronavirus SARS-CoV-2, is the sixth public
37 health emergency of international concern.[1-2] Due to this highly transmissible virus, by April 9th,
38 2020 it had been spread to five continents and approximately 85,522 people had died because of it.[2]

39 Considering transmission seems to mainly occur through contact with respiratory droplets[3]
40 produced by an infected person, anticipating public health measures intended to control and
41 prevent the infection such as adherence to universal precautions, quarantine, and timely diagnosis
42 are options available to mitigate the transmission of COVID-19.[4]

43 Clinical manifestations range from asymptomatic cases, mild upper airway infection up to
44 severe and fatal cases with pneumonia, and acute respiratory failure.[5-7] This variation is because
45 people with prior diseases/comorbidities are less apt to fight the virus so that it is more likely to
46 reach the lungs and cause pneumonia. Elderly individuals with comorbidities such as

47 Non-Communicable Diseases and immunocompromised persons are at the highest risk of
48 developing signs and symptoms of COVID-19 and having them worsened.[5-6]

49 It is, however, unknown how COVID-19 infection behaves in key populations more commonly
50 susceptible to viral diseases, such as pregnant women,[8] as well as whether there is the possibility
51 of vertical transmission to the fetus or premature birth.

52 The changes in the immune system of pregnant women make them more susceptible to
53 infectious processes, in addition to the manifestations of the infection, with the risk of adverse
54 maternal and neonatal complications, premature birth, spontaneous abortion, application of
55 endotracheal intubation, restriction of intrauterine growth, hospitalization in an intensive care unit,
56 renal failure, intravascular coagulopathy and transmission to the fetus or newborn.[9]

57 Current studies on the susceptibility of pregnant women to infection by COVID-19 are still
58 incipient and adopt poor methods, and although transmission of the virus to the fetus or baby
59 during delivery or pregnancy has not been proven, the presence of antibodies has already been
60 identified, specific IgG for viruses in neonatal serum samples.[10]

61 Due to the need to provide evidence for clinical practice involving pregnant women, this
62 study's objective was to assess current evidence presented in the literature regarding the potential
63 risks of COVID-19 infection among pregnant women and consequent fetal transmission.

64 2. Materials and Methods

65 This systematic literature review,[11] with no protocol registration, is intended to answer the
66 question: "What are the effects of COVID-19 infection during pregnancy and what is the neonatal
67 prognosis?". The PECO[12] method was adopted, in which:

- 68 • Population (P) = Pregnant women
- 69 • Exposure (E) = COVID-19 infection
- 70 • Comparison (C) = has not been an object of study
- 71 • Outcome (O): Maternal and / or fetal infection by SARS-CoV-2

72 A search was conducted in the following databases: US National Library of Medicine
73 (PubMed), Scopus, Embase, ScienceDirect (Elsevier), Web of Science (WoS), Scholar Google and
74 preprints servers bioRxiv and medRxiv, as well as the bibliographic references of the selected papers
75 (hand searching). These databases were selected due to their breadth and representativeness in the
76 field of basic and health sciences. Terms that derived from the following expressions were used
77 according to the databases/servers: "COVID-19" OR "SARS-CoV-2" AND "Pregnancy" AND
78 "Perinatal". To avoid screening biases, two researchers with expertise in the method and topic under
79 study, independently and concomitantly, though in different locations, searched all the databases on
80 May 1st and 2nd. The researchers discussed to reach a consensus about which papers would be
81 included or excluded from the study and a third reviewer mediated disagreements that prevented
82 reaching a consensus.


83 Observational epidemiological studies and case reports addressing the clinical conditions of
84 mother-fetus pairs and including primary data of patients over 18 years old were considered
85 eligible. Manuscripts that contained only data from pregnant women, or only fetuses, or that did not
86 address the period of delivery, such as puerperium, were disregarded. No restrictions regarding the
87 period of publication or language were imposed. Review papers, opinions reports, local reports,
88 abstracts of events, and similar works were excluded. Social, demographic, and clinical data
89 included in the studies were collected.

90 The GRADE system was used to classify levels of evidence. The results are presented in terms
91 of prevalence calculated in the study and combined results.

92 3. Results

93 In total, 125 studies were initially identified, 17 of which were excluded because they were
94 repeated. Of the 108 remaining studies, 48 were excluded because they did not address this review's

95 objective. The full texts of 60 studies were analyzed, though 18 did not meet the eligibility criteria so
96 that 42 studies remained and composed the final sample of this systematic review (Figure 1).



97

98

Figure 1. – Study selection flowchart.

99 The studies were divided into: 19 case reports (45%) [13-31], 15 cross-sectional descriptive studies
100 (35%) [31-46], 6 cross-sectional analytical studies (14%) [47-52], one case-control study (3%)[53] and
101 one cohort study (3%) [54] (Table 01).

Table 1. – Characteristics of included studies: reference, study design, location, level of evidence and limitations

Code	Reference	Study design	Location	Level of evidence	Limitations
1	Fan et al. (2020) [13]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up
2	Chen et al. (2020) [14]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
3	Li et al. (2020) [15]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
4	Lee et al. (2020) [16]	Case report	Asia	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
5	Xiaotong et al. (2020) [17]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
6	Zambrano et al. (2020) [18]	Case report	Honduras	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up
7	Iqbal et al. (2020) [19]	Case report	United States of America	Very Low	Small sample size; single setting; without long term follow-up; without additional assessments of the virus in amniotic fluid, umbilical cord blood or placenta tissue
8	Kang et al. (2020) [20]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
9	Lu et al. (2020) [21]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
10	Liao et al. (2020) [22]	Case report	China	Very Low	Small sample size; only third-trimester pregnant women; without information on the delivery or the isolation conditions of the newborn after delivery
11	Buonsenso et al. (2020) [23]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up
12	Lowe e Bopp (2020) [24]	Case report	Australia	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
13	Khan et al. (2020) [25]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
14	Kalafat et al. (2020) [26]	Case report	Turkey	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
15	Karami et al. (2020) [27]	Case report	Iran	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®
16	Dong et al. (2020)	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women;

	[28]					without long term follow-up
17	González et al. (2020) [29]	Case report	Spain	Very Low	Small sample size; only third-trimester pregnant women; without information on the delivery or the isolation conditions of the newborn after delivery®	
18	Alzamora et al. (2020) [30]	Case report	Peru	Very Low	Small sample size; single setting; without long term follow-up; without additional assessments of the virus in amniotic fluid, umbilical cord blood or placenta tissue®	
19	Xiong et al. (2020) [31]	Case report	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®	
20	Liu et al. (2020) [32]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up	
21	Chen et al. (2020) [33]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®	
22	Yu et al. (2020) [34]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®	
23	Zeng et al. (2020) [35]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up	
24	Chen, Liao and Shao (2020) [36]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®	
25	Liu et al. (2020) [37]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®	
26	Zhu et al. (2020) [38]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; with little information on the exams performed	
27	Chen et al. (2020) [39]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up®	
28	Chen et al. (2020) [40]	Cross-sectional descriptive	China	Very Low	Small sample size; without long term follow-up	
29	Yan et al. (2020) [41]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; without long term follow-up	
30	Breslin et al. (2020) [42]	Cross-sectional descriptive	United States of America	Very Low	Small sample size; without long term follow-up	
31	Chen et al. (2020) [43]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; without long term follow-up	
32	Ferrazzi et al. (2020) [44]	Cross-sectional descriptive	Italia	Low	Without long term follow-up; not all newborns were tested immediately after birth; without additional assessments of the virus in amniotic fluid, umbilical cord blood or placenta tissue®	

33	Nie et al. (2020) [45]	Cross-sectional descriptive	China	Very Low	Small sample size; not all newborns were tested for SARS-CoV-2; without long term follow-up.
34	Khan et al. (2020) [46]	Cross-sectional descriptive	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; without long term follow-up.
35	Zhang et al. (2020) [47]	Cross-sectional analytical	China	Low	Small sample size; single setting; lack of clear criteria to include control groups; little information on postpartum care provided to newborns.
36	Liu et al. (2020) [48]	Cross-sectional analytical	China	Low	Small sample size; no clear criteria for inclusion in the control group; absence of tomography images for monitoring therapeutic effects in ambulatory pregnant women.
37	Liao et al. (2020) [49]	Cross-sectional analytical	China	Low	Small sample size; single setting; without long term follow-up; only third-trimester pregnant women;
38	Wu et al. (2020) [50]	Cross-sectional analytical	China	Very Low	Small sample size; single setting; without long term follow-up
39	Yue et al. (2020) [51]	Cross-sectional analytical	China	Low	Small sample size; single setting; only third-trimester pregnant women.
40	Yang et al. (2020) [52]	Cross-sectional analytical	China	Low	Small sample size; single setting; only third-trimester pregnant women; not all newborns were tested for SARS-CoV-2.
41	Lin et al. (2020) [53]	Case-control	China	Very Low	Small sample size; single setting; only third-trimester pregnant women; retrospective; without clear inclusion criteria for cases and controls.
42	Yin et al. (2020) [54]	Cohort	China	Low	Small sample size; single setting; without long term follow-up; incomplete information on pregnant women; controls are 35 non-pregnant women of fertile age

103

104 In table 02, we present the characteristics of pregnant women and newborns, with social, demographic, and clinical data being collected.

105 **Table 2.** Characteristics of included studies: study design, setting and participants, clinical, laboratory and imaging findings of women and type
 106 of delivery and clinical and laboratory findings of newborns

Code	Study design	Setting and participants	Clinical, laboratory and imaging findings of women and type of delivery	Newborns' clinical and laboratory findings
[13-31]	Case report	Setting: China (11/58%), Asia (1/5%), The Netherlands (1/5%), United States of America (1/5%), Turkey (1/5%), Iran (1/5%), Peru	Pregnancy associated comorbidity (25/93% assessed): no comorbidity (16/64%), fetal distress (4/16%), placenta previa (2/8%), gestational diabetes (1/4%), gestational hypertension (1/4%), prelabor rupture of membranes (1/4%) and	- 25 Newborns - 24 assessed: normal APGAR index (21/91%), normal weight (17/74%), premature (9/39%);

	<p>(1/5%), Italy (1/5%) and Australia (1/5%);</p> <ul style="list-style-type: none"> - Participants: 27 COVID-19 infected pregnant women with laboratory confirmation (27/100%), in the second (4/15%) or third (23/85%) trimester of pregnancy, mild or moderate (22/81%) and severe (5/19%) pneumonia; - 25 newborns: tested for SARS-CoV-2 (23/92%). 	<p>thalassemia (1/4%);</p> <ul style="list-style-type: none"> - Signs and symptoms (27/100% assessed women): asymptomatic (1/4%); fever at admission (20/74%), cough (16/59%), post-partum fever (5/19%), dyspnea (5/19%), shivers (4/15%), myalgia (4/15%), sore throat (3/11%), fatigue (2/7%), chest pain (2/7%), malaise (1/4%), loss of taste and / or smell (1/4%); - Imaging (23/85% assessed women): suggestive thoracic CAT scan (22/96%); - Laboratory exams (26/96% assessed women): increased Reactive C protein (18/69%), lymphocytopenia (15/58%), leucocytosis (6/23%), neutrophilia (5/19%), interleukin 6 (2/8%), elevated alanine transaminase (1/4%), immunoglobulin G (1/4%) and immunoglobulin M (1/4%); - Delivery (25/100 deliveries): C-section (20/80%) – due to comorbidities associated with pregnancy (10/50%) and (10/50%) due to the infection; Vaginal (5/20%). - Maternal death (1/4%). 	<ul style="list-style-type: none"> - 24 newborns tested: negative for SARS-CoV-2 (23/96%); positive (1/4%); - Neonatal death (1/4%); - Isolation of mother and newborn (12/52%); - Analysis of the placenta of 4 newborns: no alterations (4/100%).
<p>[32-46] Cross-sectional Descriptive</p>	<ul style="list-style-type: none"> - Settings: China (13/86%), United States of America (1/7%) and Italy (1/7%); - Pregnant women: 459 COVID-19 infected pregnant women, laboratorial diagnosis (367/80%), clinical diagnosis (92/20%), first trimester of pregnancy (27/6%), second trimester of pregnancy (38/8%), third trimester of pregnancy (394/86%), mild or moderate pneumonia (407/89%), or severe (29/6%) pneumonia, with diagnosis of pneumonia (23/5%); - 359 newborns tested for SARS-CoV-2 (279/78%). 	<ul style="list-style-type: none"> - Pregnancy related comorbidities (347/76% assessed): no comorbidity (120/35%), fetal distress (29/8%), gestational diabetes (24/7%), prelabor rupture of membranes (11/3%), gestational hypertension (10/3%), preeclampsia (7/2%), anemia (5/1%), uterine scar (4/1%), placental abruption (4/1%), complete placenta previa (1/0,3%), thalassemia (1/0,3%) e Multiple organ dysfunction syndrome/ stillbirth (1/0,3%); - Signs and symptoms (453/99% assessed women): asymptomatic (41/9%), fever at admission (253/56%), cough (199/44%), dyspnea (52/11%), fatigue (50/11%), myalgia (44/10%), chest pain (33/7%), post-partum fever (29/6%), diarrhea (25/6%), sore throat (20/4%), malaise (4/1%), coryza (2/0,4%) and expectoration (4/0,4%); - Imaging (345/75% assessed women): suggestive thoracic CAT scan (323/94%); 	<ul style="list-style-type: none"> - spontaneous abortion on the 5th week of pregnancy (1) - 359 newborns: normal APGAR index (351/98%), premature (20%); - Weight (237/66%): normal birth weight (225/95%), low birth weight (12/5%); - Newborns tested (279/78%): SARS-CoV-2 negative (274/98%), positive (7/3%); - Neonatal death after preterm delivery at 35th week of pregnancy (1); - 88 pregnant women assessed concerning isolation of which 78 were isolated from newborns;

- [47-52] Cross-sectional analytical - Setting: China (6/100%);
- pregnant women: 117 COVID-19 infected pregnant women, laboratorial diagnosis (88/75%), clinical diagnosis (29/25%), first trimester of pregnancy (3/2%), second trimester of pregnancy (22/19%), third trimester of pregnancy (92/79%), mild or moderate pneumonia (116/99%), or severe pneumonia (1/1%);
- 93 newborns tested for SARS-CoV-2 (93/100%).
- Laboratory exams (370/81% assessed women): increased Reactive C protein (179/48%), lymphocytopenia (148/40%), leukocytosis (87/24%), elevated alanine transaminase (29/8%), elevated aspartate transaminase (28/8%), neutrophilia (9/2%), immunoglobulin G (5/1%), immunoglobulin M (4/1%) and interleukin 6 (4/1%);
- Deliveries (354 deliveries):
C-section (219/62%) – due to comorbidities associated with pregnancy (136/62%), due to the infection (70/32%), no information on motive (13/6%);
Vaginal (135/38%).
- Pregnancy related comorbidities (100/85% assessed women): no comorbidity (64/64%), gestational diabetes (7/7%), prelabor rupture of membranes (5/5%), gestational hypertension (3/3%), threat of abortion (3/3%), fetal distress (3/3%), uterine scar (2/2%), B-Lynch suture or other compression suture (2/2%), preeclampsia (1/1%), asphyxia (1/1%) and Hepatitis B infection (1/1%);
- Signs and symptoms (101/86% assessed women): asymptomatic (12/12%), fever at admission (31/31%), post-partum fever (29/29%), cough (27/27%), dyspnea (5/5%), fatigue (5/5%), chest pain (1/1%);
- Imaging (101/86% assessed women): suggestive thoracic CAT scan (96/95%);
- Laboratory exams (74/63% assessed women): increased Reactive C protein (58/78%), lymphocytopenia (57/77%), neutrophilia (57/77%) and leukocytosis (17/23%);
- Deliveries (91 deliveries):
C-section (59/65%) due to comorbidities associated with pregnancy (10/17%), due to infection (19/32%), no information on motive (30/51%);
Vaginal (32/35%).
- Analysis of the placenta of 32/9% newborns: no alterations (32/100%).
- 93 newborns: normal APGAR index (93/100%);
- Weight and prematurity (71/76%): normal birth weight (65/92%), low birth weight (6/8%), premature (7/10%);
- Newborns tested (87/94%): SARS-CoV-2 negative test (87/100%);
- Neonatal death (0);
- 45 pregnant women were assessed concerning isolation and 21 were isolated from newborns;
- Analysis of the placenta (0).
- [53] Case-control - Setting: China;
- Pregnant women: 16 pregnant women infected by COVID-19, (3/19%), gestational hypertension (2/13%), preeclampsia (14/82%), premature (3/18%);

		<p>laboratory diagnosis (16/100%), in the third trimester of pregnancy (16/100%), mild or moderate pneumonia (16/100%);</p> <ul style="list-style-type: none"> - 17 newborns: tested for SARS-CoV-2 (3/18%). 	<p>(1/6%), prelabor rupture of membranes (1/6%), Hepatitis B (1/6%);</p> <ul style="list-style-type: none"> - Medical background: hypothyroidism (2/13%) and sinus tachycardia (1/6%); - Signs and symptoms (16/100% pregnant women studied): asymptomatic (4/25%), fever at admission (4/25%), post-partum fever (8/50%); - Imaging (16/100% pregnant women studied): suggestive thoracic CAT scan (10/63%); - Laboratory exams (16/100% pregnant women studied): increased Reactive C protein (16/100%), neutrophilia (16/100%), lymphocytopenia (2/13%); - Deliveries (16 deliveries): C-section (14/87%) – does not mention motive; Vaginal (3/13%). 	<ul style="list-style-type: none"> - Newborns tested (3/18%): SARS-CoV-2 negative (3/100%); - Neonatal deaths (0); - pregnant women assessed for isolation (0); - Analysis of the placenta (0).
[54]	Cohort	<ul style="list-style-type: none"> - Setting: China; - Pregnant women: 31 pregnant women infected by COVID-19, laboratory diagnosis (31/100%), in the first trimester of pregnancy (4/13%), in the second trimester (5/16%), in the third trimester (22/71%), mild or moderate pneumonia (21/68%), severe pneumonia (10/32%); - 17 newborns tested for SARS-CoV-2 (17/100%). 	<ul style="list-style-type: none"> - Pregnancy related comorbidities (31/100% pregnant women assessed): no comorbidities (28/90%) and gestational hypertension (1/3%). - Medical background: cardiovascular disease (1/3%) and diabetes (1/3%); - Signs and symptoms (31/100% pregnant women studied): asymptomatic (5/16%), fever at admission (17/55%), cough (15/48%), dyspnea (8/26%), fatigue (6/19%), expectorations (5/16%), myalgia (3/10), diarrhea (2/6%); - Imaging (31/100% pregnant women studied): Suggestive CT tomography (31/100%); - Laboratory exams (31/100% pregnant women studied): neutrophilia (10/32%), increased aspartate transaminase (7/23%); - Deliveries (17): C-section (13/76%) – no description on the indication; Vaginal (4/24%). 	<ul style="list-style-type: none"> - 17 newborns: normal APGAR index (16/94%), normal weight (16/94%), premature (5/29%); - Newborns tested (17/100%): SARS-CoV-2 negative (17/100%); - neonatal death (0); - Pregnant women analyzed for isolation (0); - Analysis of the placenta (0).

107 The 19 case reports (45%)[13-31] addressed 27 women in the second (15%) and third trimester
108 (85%) of pregnancy, admitted with signs and symptoms of COVID-19 (96%), later confirmed
109 through RT-PCR (100%). Twenty-two (81%) developed mild to moderate pneumonia. The majority
110 of the studies were conducted in China (58%) [13-15,17,20-23,28,31] and were limited to the
111 description of the main features of the disease in positive pregnant women. As for comorbidities,
112 more than half of the women did not present any comorbidity(64%)[13,17,19,21-25,27-29,31]. Among
113 those with comorbidities, the most common one was fetal distress (16%)[16,20,22-23]. The most
114 clinical signs and symptoms were fever (74%)[13-14,16,19,22-31] and cough (59%)
115 [15-16,19-23,25-27,29,31]. Among the imaging findings, chest tomography revealed pulmonary
116 changes (96%)[13-17,19-23,25-27,29-31]. Laboratory exams revealed increased reactive C protein
117 (69%)[14-15,17,19,20,23,25,27,29-31] and decrease in lymphocytes (lymphocytopenia) (58%)
118 [13-14,17,19-20,22-23,26-29,31]. Twenty-five newborns were born from twenty-five women,
119 predominately through C-section delivery (80%)[13-17,20-23,25-26,28-30] for half of which there was
120 medical indication due to maternal comorbidities [14-16,20,22-23,26,30] or due to the infection
121 [13,17,20,23,25,28-29]. Of the 25 newborns, one died [27] along with his/her mother, and 24 were
122 tested for SARS-CoV-2: one was positive [30]. In half of the cases, newborns were isolated from
123 mothers (52%)[13-14,16-17,19-21,28,30] and in four cases the placenta was analyzed for pathological
124 alterations [13,17]. There were no cases of vertical transmission.

125 In cross-sectional descriptive studies (35%)[31-46], 11 (86%) were conducted in China
126 [32-41,45-46]. A total of 459 pregnant women were assessed for COVID-19, of which 367 (80%) were
127 diagnosed with the disease through RT-PCR. The majority (86%) were in the third trimester of
128 pregnancy and had mild to moderate pneumonia (89%). The most frequent were women not to
129 present any comorbidity (35%) [32-34,36-37,39,41,43-46]. The signs and symptoms more frequently
130 found in pregnant women were fever [32-34,37-45] and cough [32-34,36-46]. Imaging findings
131 revealed suggestive images of infection in 323 (94%) pregnant women [33,41,43,45-46] and
132 laboratory exams showed increased reactive C-protein (48%) [33-34,36-37,39-41,43-44] and
133 lymphocytopenia (40%)[33-34,36-37,39-41,43-44]. 354 pregnancies resulted in 359 newborns with 5
134 twin births. C-section was the most frequent type of delivery (62%), the majority resulting from
135 pregnancy comorbidities (62%) [32-34,36-42,44-46]. A newborn died after birth [32] and there was a
136 stillbirth [41]. Two hundred and seventy-nine newborns were tested for SARS-CoV-2, of which 7
137 tested positive (3%) [34,44-46]. Isolation of the newborn from the mother occurred in 78 (87%)
138 [42,44-45] cases. A total of 32 placentas were analyzed with no abnormal findings [45].

139 All cross-sectional analytical studies (14%) [47-52] were conducted in China, in a total of 117
140 COVID-19 infected pregnant women, with laboratory (75%) and clinical diagnosis (25%). Most
141 pregnant women were in their third trimester (79%) and had developed mild to moderate
142 pneumonia (99%). Clinical findings showed that only 36 (36%) [48-51] women had some type of
143 comorbidity (Table 2). The most common signs and symptoms were fever at admission [48-52],
144 post-partum fever [48,51-52] and cough [48-50,52].

145 Chest computed tomography was suggestive in 96 (95%) women [48-52] and laboratory exams
146 revealed increased reactive C protein (78%),[48-50], lymphocytopenia (77%)[48-50] and neutrophilia
147 (77%) [48,50]. Of the 91 women who delivered, 59 (65%) had a C-section of which 19 were due to
148 COVID-19 [47-51]. A total of 93 babies were born with one set of twins. Eighty-seven (94%) were
149 tested for SARS-CoV-2 and all were negative. Twenty-one (47%) pregnant women were isolated

150 from their newborns [49,52]. There were no neonatal deaths, no placentas were analyzed and there
151 was no confirmation of vertical transmission.

152 The case-control study (3%)[53] was conducted using the medical records of pregnant women
153 admitted to a hospital in China. The study compares the clinical features, maternal and neonatal
154 outcomes of 16 pregnant women with COVID-19 and 18 without the disease but suspected. There
155 are no clear definitions for the inclusion of participants in the case or the control group. The
156 description in Table 2 relates to COVID-19 infected pregnant women. All 16 women were in their
157 third trimester of pregnancy, of which 5 (31%) had no pregnancy-related comorbidity. The signs and
158 symptoms more frequent were fever at admission (25%) and after birth (50%). Ten women had
159 suggestive tomography and there was an increase in reactive C protein and neutrophilia in all
160 studied women. Fourteen (87%) women underwent C-section delivery. The study does not mention
161 what was the indication for having this type of delivery. A total of 17 babies were born with one set
162 of twins, with no complications. Only three newborns were tested for SARS-CoV-2 and were all
163 negative. There was no description of isolation measures after birth or analysis of the placenta.

164 The cohort study (3%)[54], also conducted in China, retrospectively describes 31 pregnant
165 women and 35 non-pregnant women with COVID-19. Only the clinical findings of pregnant women
166 are described. In total 31 pregnant women were assessed. The majority was in the third trimester of
167 pregnancy (71%), all had confirmation of diagnosis through RT-PCR, 21 (68%) developed mild to
168 moderate pneumonia, and 10 severe pneumonia. Twenty-eight did not present comorbidities during
169 pregnancy. The most prevalent signs and symptoms were fever (55%) and cough (48%). Chest
170 tomography was suggestive in all cases and abnormal laboratory tests were related to the increased
171 number of neutrophils (32%), aspartate transaminase (26%), and interleukin 6. There were 17
172 deliveries were performed, 13 (76%) of which were C-sections, the authors do not describe the
173 reason for the indication. 17 babies, single, healthy fetuses were born and tested negative for
174 SARS-CoV-2. There was no description of the isolation of the mother and baby after delivery and no
175 evaluation of the placentas.

176 4. Discussion

177 This review was intended to answer a question concerning the effects of COVID-19 infection
178 during pregnancy and neonatal prognosis. Forty-two studies were eligible and included case
179 reports, cross-sectional, analytical cross-section, case-control, and cohort presenting low levels of
180 evidence. The low levels of evidence are due to the novelty of COVID-19 pandemic and the need for
181 rapidly acquiring knowledge to support public policies. As the number of cases increases
182 worldwide, evidence about the impact of this virus during pregnancy for both women and
183 newborns is expected to become stronger, especially with the development of more robust
184 comparative studies and follow-up with control groups.

185 A total of 650 pregnant women were assessed, 557 were from China,
186 [13-15,17,20-23,25,28,31-41,43,45-54] 44 EUA,[19,42] 42 Italy,[44], and 1 and 1 pregnant woman in
187 Asia,[16] Honduras,[18] Australia,[24] Turkey,[26] Iran,[27] Spain [29] and Peru.[30] All women
188 evaluated were in the fertile period and, as for the time of pregnancy, there were pregnant women in
189 the first trimester (34/5%), in the second (69/11%) and third trimester of pregnancy (547/84%),
190 explaining why only 511 infants were born in the period. The fact that most pregnant women were
191 from China imposes a considerable challenge to interpret evidence, considering cultural and
192 epidemiological differences when comparing with pregnant women from other countries and
193 cultures. However, even in a minority (93/14%), non-Chinese pregnant women were evaluated and
194 the characteristics (clinical and epidemiological) showed no differences.

195 Regarding the pregnant women's age, the fertile period, and the length of pregnancy, the
196 studies analyzed showed a wide variation and a lack of evidence of infection by SARS-CoV-2 during
197 the first and second trimester of pregnancy. It can be inferred that, according to the low prevalence
198 of severe infection among pregnant women (45/10%), many of them could be asymptomatic and/or
199 with mild symptoms, without the need for hospital care. Corroborating this data, a Norwegian
200 cohort study of 1258 pregnant women during the influenza pandemic in 2009 showed that 226 (18%)
201 had influenza (H1N1) and only three were hospitalized. It is noteworthy that most pregnant women
202 were in the first or second trimester of pregnancy. The study authors state that there is little evidence
203 that mild influenza during pregnancy is associated with an increased risk of preeclampsia as well as
204 premature and small birth-weight babies for gestational age [55].

205 Regarding the Middle East Respiratory Syndrome (MERS), there are limited data on the
206 prevalence and clinical characteristics of MERS during pregnancy, birth, and the postnatal period. A
207 systematic review with meta-analysis recovered seven studies, which did not report spontaneous
208 abortion. The rate of premature birth was 32.1% (3 of 11), all occurring before 34 weeks of gestation.
209 Preeclampsia was described in 19.1% (1 of 7), however, no cases of premature rupture of membranes
210 or restricted fetal growth were reported. The rates of cesarean delivery and perinatal death were
211 61.8% (5 of 8) and 33.2% (3 of 10), including two stillborn and one neonatal death (4 hours after the
212 birth of an extremely premature baby), respectively. There were no reports of fetal distress, Apgar
213 score <7 at 5 minutes, neonatal asphyxia, and admission to the neonatal intensive care unit (ICU).
214 Finally, signs of vertical transmission were not found during the follow-up period in any of the
215 newborns [56].

216 According to the above, it appears that the limited data on infection with the new coronavirus
217 in early pregnancy may be related to the absence of tests performed during this period, as Apgar
218 there are asymptomatic pregnant women, with mild signs and symptoms and there is no screening
219 of these pregnant women since the beginning of pregnancy, this infection may go unnoticed or be
220 detected only after delivery. Thus, we suggest that tests for COVID-19 should be performed as a
221 routine in prenatal care.

222 It is important to note that the fact that the majority of the women evaluated in this study are at
223 the end of pregnancy, does not mean that there is a higher prevalence of cases in pregnant women in
224 the third trimester, because, as we have already discussed, there is not enough data in the scientific
225 literature such as, for example, monitoring pregnant women from the beginning of pregnancy until
226 delivery. Thus, if we calculate the time of a normal pregnancy and buy the period that the first case
227 of COVID-19 (December 2019) was described, this pregnant woman would not have given birth yet.

228 About diagnosis, the present study verifies that of the 650 pregnant women evaluated, 529
229 (81%) and 121 (10%) were diagnosed by reverse transcription followed by polymerase chain reaction
230 (RT-PCR) and clinically, respectively. The gold standard for diagnosing Covid-19 is tissue culture in
231 which the antigen is isolated, using polymerase chain reaction (PCR), which detects nucleic acid.
232 Even so, a single result not detected through RT-PCR for SARS-CoV-2 does not exclude a COVID-19
233 diagnosis, as there are various factors as e.g., inadequate sample collection, type of biological
234 sample, the time elapsed between sample collection and onset of symptoms, fluctuation of viral
235 load, that may influence a test's result. For this reason, an RT-PCR test should be repeated in another
236 sample of a patient's respiratory tract whenever there are discordances between results and
237 epidemiological conditions, especially in populations where a false positive may result in disastrous
238 consequences.

239 In total, [13-54] comorbidities related to pregnancies were evaluated and described in 514 (79%)
240 pregnant women, of which 234 (46%) did not present any comorbidity. On the other hand, pregnant
241 women who presented one or more comorbidity, prevailed, fetal distress (36 cases), gestational diabetes
242 (34 cases), gestational hypertension (17 cases), and premature rupture of the membranes (17 cases). It
243 is worth noting that the studies only reported the number of pregnant women with comorbidities,
244 however without describing whether one or more comorbidities.

245 The presence of comorbidities related to pregnancy does not seem to directly influence the
246 adverse outcomes of pregnant women and their newborns, as the two neonatal deaths were of

247 mothers without comorbidities, but who for some reason developed severe pneumonia. However, it
248 is observed that fetal distress was the most prevalent comorbidity, demonstrating that the conditions
249 of the fetus should be carefully evaluated, especially, in those asymptomatic and without
250 comorbidities. Thus, the lack of comorbidity can influence the care and attention given to pregnant
251 women so that health professionals can discriminate against detailed evaluations.[57]

252 Concerning the signs and symptoms of infection at the time of admission, 626 (96%) pregnant
253 women were evaluated[13-54], and the main signs and symptoms presented were fever at admission
254 (325/56%), coughing (273 / 44%) and dyspnea (70/11%). It is remarkable that 63 (10%) of pregnant
255 women were asymptomatic but were tested (through RT-PCR to detect SARS-CoV-2) due to
256 exposure to people diagnosed with COVID-19. They tested positive and were hospitalized. Such a
257 fact reinforces the need to follow recommendations provided by the Centers for Disease Control and
258 Prevention (CDC) to testing risk groups in contact with those diagnosed with COVID-19,[58] though
259 this approach may not be feasible in some contexts where there is a shortage of tests.

260 Regarding imaging tests, chest computed tomography (CT) was performed in 516 (79%)
261 pregnant women [13-54], with 482 pregnant women showing changes suggestive of
262 infection[13-17,19-23,25-27,29-31, 33,41,43,54-46,48-52,53-54]. CT was very useful in the initial
263 assessment at the time of admission. The most prevalent changes were in the findings of C-reactive
264 protein, which was above the normal
265 range[14-15,17,19,20,23,25,27,29-31,33-34,36-37,39-41,43-44,48-50,53] and lymphocytopenia
266 [13-14,17,19-20,22-23,26-29,31,33-34,36-37,39-41,43-44, 48-50]. Also, other tests to a lesser extent
267 showed changes: neutrophilia, leukocytosis, increased alanine transaminase, aspartate
268 transaminase, interleukin 6, immunoglobulin G, and immunoglobulin M. It is outstanding that these
269 changes in CT and laboratory findings are found in studies with the general population. [59]
270 Concerning the evaluation of imaging tests, whether they are chest X-rays or chest CTs, these can
271 assist in the diagnosis of the disease, however, they should not be taken as unanimity for
272 confirmation or exclusion of SARS-CoV-2 infection. This can be explained by the fact that different
273 bacterial and viral etiologic agents cause pulmonary infections. In this way, imaging tests such as
274 chest CT, widely used during emerging respiratory outbreaks or as in the case of the pandemic
275 currently established by COVID-19, have high sensitivity, but low specificity. Despite the
276 limitations, these tests should be used to screen, evaluate, and monitor this kind of infection. [60]®

277 Concerning childbirth, 503 were reported, with more than half of pregnant women having
278 cesarean deliveries (324/64%). When checking the indications for cesarean section, in 156 pregnant
279 women, pregnancy-related comorbidities were the cause, 99 were described in the studies as an
280 indication for infection, and 69 did not provide a description of the indication. Regarding the
281 indication for cesarean section because of the infection, the indications were not reported. In most
282 cases, the time of delivery was determined by obstetric indications, rather than the maternal
283 diagnosis of COVID-19.[61]

284 The decision for the type of delivery is usually more influenced by the presence of maternal
285 and/or fetal impairment. When there were imminent risks, emergency cesarean section was the
286 alternative, which has happened in the case of SARS-CoV-2 infections in which the pregnant
287 woman's clinical condition is complex. However, in the presence of COVID-19, the threshold for
288 cesarean delivery became lower than usual so that infection control procedures could be more easily
289 adhered to and the transmission of the disease to the fetus minimized.[62]

290 Regarding the characteristics of the newborns, 511 babies were born, being 503 single, and 8
291 twins. The normal Apgar score and normal birth weight were verified in 498 (97%) and 337 (66%)
292 newborns, respectively. A total of 410 (80%), 96 (19%) and 10 (2%) newborns were tested for
293 SARS-CoV-2 [8 (2%) were positives], premature and underweight at birth (<2,500g), respectively
294 [30,34,44-46]. Two neonatal deaths [27,32] and one spontaneous abortion [41] have been reported.
295 After delivery, isolation between mothers and newborns was carried out in 117 pregnant women
296 [13-14,16-17,19-21,28,30,42,44-45], as well as no changes were found placental in the 36 samples
297 evaluated [13,17,45].

298 It is observed that the majority of newborns did not have serious complications. The
299 unfavorable outcomes refer to two neonatal deaths, a spontaneous abortion, a maternal death,
300 together with a stillbirth, eight (2%) positive SARS-CoV-2 tests, and three newborns with high rates
301 of IgG and IgM antibodies against SARS-CoV-2.

302 Concerning neonatal deaths, the first death was described in the study by Liu et al. [32], a
303 31-year-old pregnant woman in her third trimester of pregnancy was confirmed laboratory with
304 SARS-CoV-2. Although the pregnant woman had no previous illnesses, she had complications and
305 was admitted to the ICU due to Acute Respiratory Distress Syndrome (ARDS), Acute Liver Failure,
306 Acute Kidney Failure, Multiple Organ Dysfunction Syndrome (MODS) and septic shock. The
307 pregnant woman was intubated, received mechanical ventilation, and an emergency cesarean
308 section was performed due to premature labor. The fetus was born with an Apgar score of 1 and did
309 not survive. The mother recovered. According to the study, the serological evidence was not
310 suggestive of vertical transmission of the virus.

311 The second case is described by Yan et al.[41], a 32-year-old pregnant woman was confirmed
312 with COVID-19 by RT-PCR in the third trimester of pregnancy. After the hospital admission, her
313 condition worsened, she developed severe pneumonia and septic shock, requiring ICU admission
314 for endotracheal intubation and invasive ventilation. She underwent a cesarean section in her 35th
315 gestational week and gave birth to a newborn baby who remained with Apgar of 1 in the 1st, 5th,
316 and 10th minutes after delivery. Severe neonatal asphyxia and the need for invasive ventilation have
317 been reported, but the newborn died within two hours of birth. In this same retrospective study, the
318 authors briefly cited the case of a woman, in the 5th gestational week, who had a spontaneous
319 abortion. It is believed that the brevity of the data description was due to the lack of information in
320 the medical records.

321 Karami et al.[27] reported the death of a mother and her baby. The pregnant woman was 27
322 years old, in the 30th gestational week, and SARS-CoV-2 infection diagnosed by RT-PCR only after
323 delivery. The patient had no underlying disease, however, she had fever, cough, myalgia, and
324 dyspnea and was referred to the hospital. Due to tachypnea, oxygen saturation below 95%,
325 tachycardia, and high fever, the patient had to be transferred to the ICU. Abnormal findings were
326 found in imaging tests, leukopenia, thrombocytopenia, elevated levels of C-reactive protein, and
327 lactate dehydrogenase. Due to a worsening of clinical symptoms, the patient required endotracheal
328 intubation and invasive ventilation. The following day, premature spontaneous delivery occurred
329 vaginally to a fetus with an Apgar score of 0 during the 1st and 5th minute after birth, which did not
330 change with the attempt at neonatal cardiopulmonary resuscitation. After new atypical laboratory
331 and imaging tests, the medical team became suspicious of acute autoimmune vascular disease,
332 initiating treatment without success. The mother died of multiple organ failure.

333 Regarding the eight newborns who tested positive for SARS-CoV-2, two of them tested positive
334 [46], immediately, after delivery, however they tested negative after 24 hours of delivery. Another
335 newborn tested positive 36 hours after delivery [34]. It is important to note that, in these three cases,
336 the isolation or not of the mother and babies after delivery is not described. Besides the authors of
337 these three studies assumed the lack of evidence for vertical transmission due to the absence of
338 intrauterine tissue and amniotic fluid samples.

339 Two newborns tested positive for the new coronavirus after being breastfed by their mothers
340 without wearing masks, as the maternal infection was not known in the postpartum period.
341 However, vertical transmission could not be confirmed or ruled out, as the authors stressed that
342 testing for COVID-19 was not performed on newborns, immediately after birth. Moreover, in this
343 same study, a pregnant woman with COVID-19 gave birth to a newborn by vaginal delivery, who
344 tested positive for SARS-CoV-2, despite the mother's wearing a surgical mask and the medical team
345 wearing the adequate PPE throughout labor [44]. The other two newborns tested positive 16
346 hours[30] and 53 hours[45] after delivery, respectively. Both studies described that the guidelines
347 were followed: the use of a mask by the mother, the entire medical team was attired, the mother and
348 baby were isolated after delivery and there was no breastfeeding. However, the authors revealed an
349 important limitation of the study, the absence of complementary assessments (presence of viruses in

350 amniotic fluid, umbilical cord blood, or placental tissue). Of the eight positive babies, two were
351 intubated[30,44], three had mild pneumonia[34,45-46], but in a few days, they were fully recovered.®

352 Dong et al.[28] reported the case of a newborn who, shortly after birth, had leukocytosis, a high
353 rate of IgG and IgM antibodies against SARS-CoV-2 and IL-6 cytokines, however, the baby had no
354 symptoms and the test for the virus it was negative. Although the newborn was tested negative for
355 SARS-CoV-2, the authors stated that the high rate of IgM antibodies within 2 hours after birth
356 suggested the occurrence of intrauterine infection, as there would be no transfer of these antibodies
357 from the mother to the fetus through the placenta due to the size of this macromolecule and, in
358 general, they take three to seven days to be produced by the body after contact with the infectious
359 agent, however, they do not rule out the possibility of infection during delivery.®

360 Zeng et al. [35] described similar results regarding the assessment of the presence of specific
361 antibodies against SARS-CoV-2 in the blood of newborns from mothers with confirmed COVID-19
362 infection. Two babies had rates of IgG and IgM antibodies specific to the virus above the normal
363 level, but none showed symptoms of the infection. The authors of this study stressed the possibility
364 that the newborn developed IgM antibodies during the gestational period if the virus had crossed
365 the placental barrier.®

366 Finally, the studies recovered in this review have several limitations, among them, the fact of
367 the reduced sample size; use of a single institution; retrospective evaluation of medical records
368 where incomplete data exist and this can be observed by checking the number of pregnant women
369 who were recruited and those who were evaluated for comorbidities, signs and symptoms, tests, as
370 well as the babies who were born and those who were tested for infection; the use of the database of
371 notification systems where different authors may have included the same pregnant women,
372 however, this fact may have been positive if the justification is to carry out a different approach and
373 increase the sample size for possible comparisons; most of the cases described are in Chinese
374 pregnant women; absence of a standard of assessment in newborns such as the presence of viruses in
375 amniotic fluid, umbilical cord blood or placental tissue; scarce information about care during
376 delivery and postpartum; absence of clear criteria for inclusion in a control group. However, even
377 with these limitations, the strengths of this review is the ability to compare all the literature available
378 so far, compile loose data and group it more clearly for analysis and inferences and, state, based on
379 what was assessed that there is no evidence of vertical transmission so far, as there are gaps
380 concerning the care taken during and after delivery, and biological sample proper for testing the
381 SARS-CoV-2.

382 5. Conclusions

383 In summary, the results found in this review show that health professionals cannot rule out a
384 possible worsening of the clinical picture of the pregnant woman infected with SARS-CoV-2 because
385 she is asymptomatic or does not have comorbidities related to gestation. Pregnant women and
386 health professionals should be cautious and vigilant, as soon as their pregnancy is confirmed, with
387 or without confirmed infection, as this review checks for infected pregnant women in all trimesters
388 of pregnancy. Thus, in times of this pandemic, it is important to monitor and screen pregnant
389 women for COVID-19 from the time pregnancy is confirmed.

390 **Author Contributions:** AFLS, HEFC, LBO, GS, and IF had the idea for and designed the study and had full
391 access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the
392 data analysis. AFLS, HEFC, LBO, GS, IF, ELSC, EW, DA, AFC, and IACM did the analysis, and all authors
393 critically revised the manuscript for important intellectual content. All authors gave final approval for the
394 version to be published. All authors agree to be accountable for all aspects of the work in ensuring that
395 questions related to the accuracy or integrity of any part of the work are appropriately investigated and
396 resolved.

397 **Funding:** Coordenação de Aperfeiçoamento de Pessoal do Nível Superior (CAPES-Brazil) and Conselho
398 Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil).

399 **Conflicts of Interest:** The authors no reported conflicts of interest.

400

401 **Conflicts of Interest:** The authors no reported conflicts of interest.

402 **References**

- 403 1. Chih-Cheng, L.; Tzu-Ping, S.; Wen-Chien, K.; et al. Severe acute respiratory syndrome coronavirus 2
404 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int j of*
405 *antimicrob agents*. **2020**,55(3),105924.
- 406 2. WHO. Coronavirus disease 2019 (COVID-19). Situation Report – 80. Available from:
407 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_2)
408 [pdf?sfvrsn=1b685d64_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200409-sitrep-80-covid-19.pdf?sfvrsn=1b685d64_2)
- 409 3. Centers for Disease Control and Prevention (CDC). Coronavirus. Available from: [https://www.](https://www.cdc.gov/coronavirus/index.html)
410 [cdc.gov/coronavirus/index.html](https://www.cdc.gov/coronavirus/index.html).
- 411 4. Perlman, S. Another decade, another coronavirus. *N Engl J Med* **2020**,882, 760–62.
- 412 5. Chen, N.; Zhou, M.; Dong, X.; et al. Epidemiological and clinical characteristics of 99 cases of 2019
413 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. **2020**,395(10223),507–513.
- 414 6. Huang, C.; Wang, Y.; Li, X.; et al. Clinical feature of patients infected with 2019 novel coronavirus in
415 Wuhan, China. *Lancet* **2020**, 395, (10223), 497–506.
- 416 7. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. *N Engl J Med*. **2014** 5;370(23):2211-8. doi:
417 10.1056/NEJMra1213566.
- 418 8. Wang, D.; Hu, B.; Hu, C.; et al. Clinical characteristics of 138 hospitalized patients with 2019 novel
419 coronavirus-infected pneumonia in Wuhan, China. *JAMA* **2020**, 323(11), 1061–1069.
- 420 9. Qiao, J. What are the risks of COVID-19 infection in pregnant women? 2020; 395 (10226) : 760-62
- 421 10. Zeng, H.; Xu, C.; Fan, J.; et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia.
422 *JAMA* **2020**, [ahead of print].
- 423 11. Peters, MD.; Godfrey, CM.; McInerney, P.; et al. The Joanna Briggs Institute reviewers' manual **2015**:
424 methodology for JBI scoping reviews 2015.
- 425 12. Moher, D.; Liberati, A.; Tetzlaff, J.; et al. Preferred reporting items for systematic reviews and
426 meta-analyses: the PRISMA statement. *PLoS Med* **2009**, 6(7), e1000097.
- 427 13. Fan, C.; Lei, D.; Fang, C.; et al. Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should
428 We Worry? *Clin Infect Dis* **2020**, ciaa226.
- 429 14. Chen, S.; Huang, B.; Luo, DJ.; et al. Pregnant women with new coronavirus infection: a clinical
430 characteristics and placental pathological analysis of three cases. *Zhonghua Bing Li Xue Za Zhi* **2020**,
431 49(0), E005.
- 432 15. Li, Y.; Zhao, R.; Zheng, S.; et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome
433 Coronavirus 2, China. *Emerg Infect Dis* **2020**, 26(6).
- 434 16. Lee, DH.; Lee, J.; Kim, E.; et al. Emergency cesarean section on severe acute respiratory syndrome
435 coronavirus 2 (SARS- CoV-2) confirmed patient. *Korean J Anesthesiol* **2020**, [ahead of print].
- 436 17. Xiaotong, W.; Zhiqiang, Z.; Jianping, Z.; et al. A case of 2019 Novel Coronavirus in a pregnant woman
437 with preterm delivery. *Clinical Infectious Diseases* **2020**, ciaa200.
- 438 18. Zambrano, L.; Fuentes-Barahona IC.; Bejarano-Torres, DA.; et al. A pregnant woman with COVID-19
439 in Central America. *Travel Med Infect Dis* 2020, 101639(10.1016).
- 440 19. Iqbal, SN.; Overcash, R.; Mokhtari, N.; et al. An Uncomplicated Delivery in a Patient with Covid-19 in
441 the United States. *N Engl J Med* 2020, 382:e34.
- 442 20. Kang, X.; Zhang, R.; He, Huiliang.; et al. Anesthesia management in cesarean section for a patient with
443 coronavirus disease 2019. *J Zhejiang Univ* 2020, 49(2):249-52.
- 444 21. Lu, D.; Sang, Lin.; Du, Shihua.; et al. Asymptomatic COVID-19 infection in late pregnancy indicated no
445 vertical transmission. *J Med virol* 2020:1-5.

- 446 22. Liao, X.; Yang, H.; Kong, J.; et al. Chest CT Findings in a Pregnant Patient with 2019 Novel
447 Coronavirus Disease. *Balkan Med J* 2020, [Epub ahead of print].
- 448 23. Buonsenso, D.; Raffaelli, F.; Tamburrini, E.; et al. Clinical role of lung ultrasound for the diagnosis and
449 monitoring of COVID-19 pneumonia in pregnant women. *Ultrasound Obstet Gynecol* 2020, [Epub
450 ahead of print].
- 451 24. Lowe, B.; Bopp, B. COVID-19 vaginal delivery - a case report. *Aust N Z J Obstet Gynaecol* 2020, [Epub
452 ahead of print].
- 453 25. Khan, S.; Peng, L.; Siddique, R.; et al. Impact of COVID-19 infection on pregnancy outcomes and the
454 risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. *Infect Control
455 Hosp Epidemiol* 2020, [Epub ahead of print].
- 456 26. Kalafat, E.; Yaprak, E.; Cinar, G.; et al. Lung ultrasound and computed tomographic findings in
457 pregnant woman with COVID-19. *Ultrasound Obstet Gynecol* 2020, [Epub ahead of print].
- 458 27. Karami, P.; Naghavi, M.; Feyzi, A.; et al. Mortality of a pregnant patient diagnosed with COVID-19: A
459 case report with clinical, radiological, and histopathological findings. *Travel Med Infect Dis* 2020,
460 [Epub ahead of print].
- 461 28. Dong, L.; Tian, J.; He, S.; et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother
462 to Her Newborn. *JAMA* 2020, [Epub ahead of print]
- 463 29. González, R.; Ocampo, P.J.; González BL.; et al. Pregnancy and perinatal outcome of a woman
464 with COVID-19 infection. *Rev Clin Esp* 2020, [Epub ahead of print].
- 465 30. Alzamora, MC.; Paredes, T.; Caceres D.; et al. Severe COVID-19 during Pregnancy and Possible
466 Vertical Transmission. *Am J Perinatol* 2020, [Epub ahead of print].
- 467 31. Xiong, X.; Wei, H.; Zhang, Z.; et al. Vaginal delivery report of a healthy neonate born to a convalescent
468 mother with COVID-19. *J Med Virol* 2020, [Epub ahead of print].
- 469 32. Liu, Y.; Chen, H.; Tang, K.; et al. Clinical manifestations and outcome of SARS-CoV-2 infection during
470 pregnancy. *J Infect* 2020, piiS0163-4453(20),30109-2. [ahead of print].
- 471 33. Chen, H.; Guo, J.; Wang, C.; et al. Clinical characteristics and intrauterine vertical transmission
472 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.
473 *Lancet* 2020, 395 (10226), 809-815.
- 474 34. Yu, N.; Li, W.; Kang, Q.; et al. Clinical features and obstetric and neonatal outcomes of pregnant
475 patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet
476 Infect Dis* 2020, S1473-3099(20),30176-6. [ahead of print].
- 477 35. Zeng, H.; Xu, C.; Fan, J.; et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia.
478 *JAMA* 2020, [ahead of print].
- 479 36. Chen, S.; Liao, E.; Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus
480 pneumonia. *J Med Virol* 2020, [ahead of print].
- 481 37. Liu, D.; Li, L.; Wu, X.; et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease
482 (COVID-19) Pneumonia: A Preliminary Analysis. *AJR Am J Roentgenol* 2020, 18, 1-6. [ahead of print].
- 483 38. Zhu, H.; Wang, L.; Fang, C.; et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV
484 pneumonia. *Transl Pediatr* 2020, 9 (1):51-60
- 485 39. Chen, H.; Guo, J.; Wang, C.; et al. Clinical characteristics and intrauterine vertical transmission
486 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.
487 *Lancet* 2020, 395(10226): 809-815.
- 488 40. Chen, L.; Qin, L.; Zheng, D.; et al. Clinical Characteristics of Pregnant Women with Covid-19 in
489 Wuhan, China. *N Engl Med* 2020:1-3.

- 490 41. Yan, J.; Guo, J.; Fan, C.; et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report
491 based on 116 cases. *Am J Obstet Gynecol* **2020**, [Epub ahead of print].
- 492 42. Breslin, N.; Baptiste, C.; Gyamfi-Bannerman, C.; et al. COVID-19 infection among asymptomatic and
493 symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New
494 York City hospitals. *Am J Obstet Gynecol MFM* **2020**, [Epub ahead of print].
- 495 43. Chen, R.; Zhang Y.; Huang, L.; et al. Safety and efficacy of different anesthetic regimens for parturients
496 with COVID-19 undergoing Cesarean delivery: a case series of 17 patients. *Can J Anaesth* **2020**, [Epub
497 ahead of print].
- 498 44. Ferrazi, E.; Frigerio, L.; Savasi, V.; et al. Vaginal delivery in SARS-CoV-2 infected pregnant women in
499 Northern Italy: a retrospective analysis. *BJOG* **2020**, [Epub ahead of print].
- 500 45. Nie, R.; Wang, S.; Yang, Q.; et al. Clinical features and the maternal and neonatal outcomes of pregnant
501 women with coronavirus disease 2019. *medRxiv* **2020**.
- 502 46. Khan, S.; Jun, Li.; Nawsherwan.; et al. Association of COVID-19 with pregnancy outcomes in
503 health-care workers and general women. *Clin Microbiol Infect* **2020**, [Epub ahead of print].
- 504 47. Zhang, L.; Jiang, Y.; Wai, M.; Cheng, BH.; Zhou, XC.; Li J. Analysis of the pregnancy outcomes in
505 pregnant women with COVID-19 in Hubei Province. *Zhonghua Fu Chan Ke Za Zhi* **2020**, *55*, E009.
- 506 48. Liu, H.; Liu, F.; Li, J.; et al. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on
507 pregnant women and children. *J Infect* **2020**, pii S0163-4453(20), 30118–3. [ahead of print]
- 508 49. Liao, J.; He, Xiaoyan.; Gong, Q. et al.; Analysis of vaginal delivery outcomes among pregnant women
509 in Wuhan, China during the COVID-19 pandemic. *Int J Gynaecol Obstet* **2020**, [Epub ahead of print].
- 510 50. Wu, X.; Sun, R.; Chen, J.; et al. Radiological findings and clinical characteristics of pregnant women
511 with COVID-19 pneumonia. *Int J Gynaecol Obstet* **2020**, [Epub ahead of print]
- 512 51. Yue, L.; Han, L.; Li, Q.; et al. Anaesthesia and infection control in cesarean section of pregnant women
513 with coronavirus disease 2019 (COVID-19) *medRxiv* **2020**.
- 514 52. Yang, Hui.; Sun, G.; Tang, F.; et al. Clinical features and outcomes of pregnant women suspected of
515 coronavirus disease 2019. *J Infect* **2020**, [Epub ahead of print]
- 516 53. Lin, N.; Han, L.; Peng, M.; et al. Maternal and neonatal outcomes of pregnant women with COVID-19
517 pneumonia: a case-control study. *Clin Infect Dis* **2020**, [Epub ahead of print].
- 518 54. Yin, M.; Zhang L.; Deng, G.; et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
519 Infection During Pregnancy In China: A Retrospective Cohort Study. *medRxiv* **2020**.
- 520 55. Laake, I.; Tunheim, G.; Robertson, AH.; et al. Risk of pregnancy complications and adverse birth
521 outcomes after maternal A(H1N1) pdm 09 influenza: a Norwegian population-based cohort study.
522 *BMC Infect Dis* **2018**, *18*(1), 525.
- 523 56. Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus
524 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus
525 Infections. *Viruses* **2020**, *12*(2).
- 526 57. Gidlöf, S., Savchenko, J., Brune, T. et al. COVID-19 in pregnancy with comorbidities: More liberal
527 testing strategy is needed. *Acta Obstet Gynecol Scand.* **2020**. [ahead of print]
- 528 58. Centers for Disease Control and Prevention (CDC). Interim Considerations for Infection Prevention
529 and Control of Coronavirus Disease 2019 (COVID-19) in Inpatient Obstetric Healthcare Settings.
530 Available from:
531 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html>
- 532 59. WHO. Coronavirus disease 2019 (COVID-19). Situation Report – 72. Available from:
533 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2
534

- 535
536
537
538
539
540
541
542
543
60. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*. 2020. [ahead of print]
 61. National Institutes of Health. Special Considerations in Pregnancy and Post-Delivery. 12 My. 2020. Available from: <https://www.covid19treatmentguidelines.nih.gov/overview/pregnancy-and-post-delivery/>
 62. Ashokka, B. Care of the Pregnant Woman with COVID-19 in Labor and Delivery: Anesthesia, Emergency cesarean delivery, Differential diagnosis in the acutely ill parturient, Care of the newborn, and Protection of the healthcare personnel. *Am J Obst Gynec*. 2020 [ahead of print]